HBM HOLDINGS-B (02142) gained nearly 4% in afternoon trading, rising 3.15% to HKD 13.76 by the time of writing, with a turnover of HKD 33.42 million. The company recently announced an update and expansion of its global strategic collaboration with AstraZeneca PLC, initially established in March 2025. Under the agreement, both parties will leverage their respective expertise to jointly discover and develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).

AstraZeneca will nominate research projects annually over the next four years and retain licensing options for these projects, reflecting the deepening partnership. HBM HOLDINGS-B is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed products. The financial terms align with the framework agreed upon by both parties in March 2025.